Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. (1877)

Market Closed
10 Aug, 08:00
HKEX HKEX
19. 42
HKD
-0.06
-0.308%
HKD
- Market Cap
- P/E Ratio
- Div Yield
2.89M Volume
-1.73 Eps
19.48 HKD
Previous Close
Add Transaction
Day Range
19.2 20.32
Year Range
15.25 38.64
Want to track 1877 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1877 closed yesterday lower at 19.42 HKD, a decrease of -0.308% from Friday's close, completing a monthly increase of 4.973% or 0.92 HKD. Over the past 12 months, 1877 stock lost -8.8263%.
1877 is not paying dividends to its shareholders.
The last earnings report, released on Apr 24, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on HKEX (HKD).

1877 Chart

Shanghai Junshi Biosciences Co., Ltd. (1877) FAQ

What is the stock price today?

The current price is 19.42 HKD.

On which exchange is it traded?

Shanghai Junshi Biosciences Co., Ltd. is listed on HKEX.

What is its stock symbol?

The ticker symbol is 1877.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Shanghai Junshi Biosciences Co., Ltd. ever had a stock split?

No, there has never been a stock split.

Shanghai Junshi Biosciences Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Jun Xiong CEO
HKEX Exchange
CNE100003FF7 ISIN
DE Country
2,903 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Shanghai Junshi Biosciences Co., Ltd. is a prominent biopharmaceutical company focused on the pioneering discovery, development, and commercialization of innovative drugs. Established in 2012 and based in Shanghai, People's Republic of China, the company has dedicated itself to addressing complex health challenges. It operates within the dynamic landscape of the biopharmaceutical industry, primarily targeting therapeutic areas such as oncology, metabolic disorders, autoimmune diseases, neurologic conditions, nervous system disorders, and infectious diseases. Shanghai Junshi Biosciences aims to leverage cutting-edge science and technology to bring forth novel treatments that can significantly improve patient outcomes across the People's Republic of China.

Products and Services

Shanghai Junshi Biosciences Co., Ltd. offers a broad spectrum of products and services designed to meet the diverse needs of patients suffering from a wide range of conditions. Their portfolio includes:

  • Oncology Treatments: The company has developed and commercialized innovative therapies for the treatment of various cancers. These treatments focus on improving survival rates and quality of life for cancer patients through targeted therapies and immunotherapies that leverage the body’s own immune system to fight cancer.
  • Metabolic Disorder Therapies: Addressing the growing global challenge of metabolic disorders, Shanghai Junshi Biosciences provides treatments aimed at regulating metabolic processes. These therapies help in managing conditions such as diabetes, obesity, and related complications, thereby improving patient health and well-being.
  • Autoimmune Disease Solutions: With a focus on autoimmune disorders, the company develops drugs that modulate the immune system, providing relief from the chronic and often debilitating symptoms associated with conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
  • Neurologic and Nervous System Treatments: Recognizing the complexity of neurologic and nervous system disorders, Shanghai Junshi Biosciences offers therapies aimed at addressing conditions such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease, striving to restore function and improve quality of life.
  • Infectious Disease Medications: In response to the global threat posed by infectious diseases, the company has developed treatments targeting various infectious agents. These include therapies for viral, bacterial, and fungal infections, aiming to reduce morbidity and prevent the spread of infectious diseases.

Contact Information

Address: Building 7, Shanghai, China, 200126
Phone: 86 21 6105 8800